Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | GRK6 | P43250 | 1/20 | 0.32 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17688704 | 1.00 | RAB9A (0.39) | RAB9ANPC1TAS1R3TAS1R1GAA | |
| SCHEMBL17688701 | 1.00 | RAB9A (0.39) | RAB9ANPC1TAS1R3TAS1R1GAA | |
| SCHEMBL17688700 | 1.00 | RAB9A (0.39) | RAB9ANPC1TAS1R3TAS1R1GAA | |
| SCHEMBL28553100 | 0.85 | RAB9A (0.47) | RAB9ANPC1TAS1R3TAS1R1GAA | |
| SCHEMBL29185240 | 0.85 | RAB9A (0.47) | RAB9ANPC1TAS1R3TAS1R1GAA | |
| SCHEMBL17695888 | 0.85 | RAB9A (0.47) | RAB9ANPC1TAS1R3TAS1R1GAA | |
| SCHEMBL21112252 | 0.79 | CA1 (0.39) | RAB9ANPC1HAO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21112253 | 0.79 | CA1 (0.39) | RAB9ANPC1HAO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21112254 | 0.79 | CA1 (0.39) | RAB9ANPC1HAO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22612074 | 0.79 | CA1 (0.39) | RAB9ANPC1HAO1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113302185-B | Benzofuran-6-carboxamide derivatives, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-113302185-A | Benzofuran-6-carboxamide derivatives, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20200339566-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. | 2020-10-29 | — | — | US | disclosed |
| EP-3207043-B3 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3207043-B1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10087184-B2 | Dihydropyrrolopyridine inhibitors of RORγ | VITAE PHARMACEUTICALS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180222902-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
| US-9796710-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3207043-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170081327-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-03-23 | — | — | US | disclosed |
| US-9481674-B1 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-2016061160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222902-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | RAB9A 977/4885NPC1 1355/4885TAS1R3 3920/4885 |
| US-20170081327-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | RAB9A 848/4885NPC1 1504/4885TAS1R3 4344/4885 |
| US-10087184-B2 | Dihydropyrrolopyridine inhibitors of RORγ | RORC, RORB, RORA | RAB9A 1323/4885NPC1 738/4885TAS1R3 2823/4885 |
| US-20200339566-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | RAB9A 977/4885NPC1 1355/4885TAS1R3 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.